MYL has reached a $465 million settlement with the Department of Justice on EpiPen.  This removes the overhang.

MYL now expects  2016 earnings in the range of $4.70 to $4.90 per share excluding items.  Prior guidance was $4.85 to $5.15.

MYL also reaffirmed 2018 target of $6.00 per share.

The point here is that at about 7 forward PE, the stock is very cheap for the long-term investor.

The new buy zone is $35 to $39.56.  Target zone remains $48 to $49.

What To Do Now

Those in the stock may continue to hold.

Those not in the stock may consider scaling in a position in the buy zone.